These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 27837176)

  • 1. Chondrocyte proliferation, viability and differentiation is declined following administration of methylphenidate utilized for the treatment of attention-deficit/hyperactivity disorder.
    Gumustas F; Yilmaz I; Sirin DY; Gumustas SA; Batmaz AG; Isyar M; Akkaya S; Mahirogullari M
    Hum Exp Toxicol; 2017 Sep; 36(9):981-992. PubMed ID: 27837176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the negative impact of phenyl alkanoic acid derivative, a frequently prescribed drug for the suppression of pain and inflammation, on the differentiation and proliferation of chondrocytes.
    Gumustas SA; Yilmaz İ; Isyar M; Sirin DY; Batmaz AG; Ugras AA; Oznam K; Ciftci Z; Mahirogullari M
    J Orthop Surg Res; 2016 Jun; 11(1):70. PubMed ID: 27363505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
    Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
    Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children].
    Pan XX; Ma HW; Wan B; Dai XM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Aug; 10(4):471-4. PubMed ID: 18706164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylphenidate Promotes Premature Growth Plate Closure: In Vitro Evidence.
    Pazos-Pérez A; Piñeiro-Ramil M; Franco-Trepat E; Guillán-Fresco M; López-López V; Jorge-Mora A; Alonso-Pérez A; Gómez R
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder.
    Faraone SV; Spencer T; Aleardi M; Pagano C; Biederman J
    J Clin Psychopharmacol; 2004 Feb; 24(1):24-9. PubMed ID: 14709943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder.
    Kent JD; Blader JC; Koplewicz HS; Abikoff H; Foley CA
    Pediatrics; 1995 Aug; 96(2 Pt 1):320-5. PubMed ID: 7630692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder.
    Golubchik P; Weizman A
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):429-432. PubMed ID: 28398816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate.
    Ponsa I; Ramos-Quiroga JA; Ribasés M; Bosch R; Bielsa A; Ordeig MT; Morell M; Miró R; de Cid R; Estivill X; Casas M; Bayés M; Cormand B; Hervás A
    Mutat Res; 2009 Jun; 666(1-2):44-9. PubMed ID: 19457516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder.
    Park SY; Kim EJ; Cheon KA
    J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):633-40. PubMed ID: 26402385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder.
    Zheng Y; Liang JM; Gao HY; Yang ZW; Jia FJ; Liang YZ; Fang F; Li R; Xie SN; Zhuo JM
    Chin Med J (Engl); 2015 Nov; 128(22):2988-97. PubMed ID: 26608976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
    Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder.
    Tzang RF; Wang YC; Yeh CB; Hsu CD; Liang HY; Yang PC; Liu HJ; Huang YS; Cheng H; Hsu YC; Liu SI; Pan CH; Huang YF; Huang CF; Wu YY; Huang YH; Liu HC; Chang HL
    Psychiatry Clin Neurosci; 2012 Feb; 66(1):53-63. PubMed ID: 22250610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
    Işeri E; Kiliç BG; Senol S; Karabacak NI
    Methods Find Exp Clin Pharmacol; 2007; 29(1):47-52. PubMed ID: 17344944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.